164 related articles for article (PubMed ID: 9632357)
1. Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.
Law H; Dukat M; Teitler M; Lee DK; Mazzocco L; Kamboj R; Rampersad V; Prisinzano T; Glennon RA
J Med Chem; 1998 Jun; 41(13):2243-51. PubMed ID: 9632357
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
[TBL] [Abstract][Full Text] [Related]
3. 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
Chambers MS; Street LJ; Goodacre S; Hobbs SC; Hunt P; Jelley RA; Matassa VG; Reeve AJ; Sternfeld F; Beer MS; Stanton JA; Rathbone D; Watt AP; MacLeod AM
J Med Chem; 1999 Feb; 42(4):691-705. PubMed ID: 10052976
[TBL] [Abstract][Full Text] [Related]
4. 2-(1-Naphthyloxy)ethylamines with enhanced affinity for human 5-HT1D beta (h5-HT1B) serotonin receptors.
Ismaiel AM; Dukat M; Law H; Kamboj R; Fan E; Lee DK; Mazzocco L; Buekschkens D; Teitler M; Pierson ME; Glennon RA
J Med Chem; 1997 Dec; 40(26):4415-9. PubMed ID: 9435911
[TBL] [Abstract][Full Text] [Related]
5. Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.
Choi SK; Green D; Ho A; Klein U; Marquess D; Taylor R; Turner SD
J Med Chem; 2008 Jun; 51(12):3609-16. PubMed ID: 18507369
[TBL] [Abstract][Full Text] [Related]
6. Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors.
Glennon RA; Hong SS; Bondarev M; Law H; Dukat M; Rakhi S; Power P; Fan E; Kinneau D; Kamboj R; Teitler M; Herrick-Davis K; Smith C
J Med Chem; 1996 Jan; 39(1):314-22. PubMed ID: 8568822
[TBL] [Abstract][Full Text] [Related]
7. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
[TBL] [Abstract][Full Text] [Related]
8. 2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.
Prisinzano T; Dukat M; Law H; Slassi A; MacLean N; DeLannoy I; Glennon RA
Bioorg Med Chem Lett; 2004 Sep; 14(18):4697-9. PubMed ID: 15324890
[TBL] [Abstract][Full Text] [Related]
9. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines.
Lesage AS; Wouters R; Van Gompel P; Heylen L; Vanhoenacker P; Haegeman G; Luyten WH; Leysen JE
Br J Pharmacol; 1998 Apr; 123(8):1655-65. PubMed ID: 9605573
[TBL] [Abstract][Full Text] [Related]
10. The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
Gaster LM; Blaney FE; Davies S; Duckworth DM; Ham P; Jenkins S; Jennings AJ; Joiner GF; King FD; Mulholland KR; Wyman PA; Hagan JJ; Hatcher J; Jones BJ; Middlemiss DN; Price GW; Riley G; Roberts C; Routledge C; Selkirk J; Slade PD
J Med Chem; 1998 Apr; 41(8):1218-35. PubMed ID: 9548813
[TBL] [Abstract][Full Text] [Related]
11. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
[TBL] [Abstract][Full Text] [Related]
12. Imidazoline-modified benzylimidazolines as h5-HT(1D/1B) serotonergic ligands.
Prisinzano T; Law H; Dukat M; Slassi A; MaClean N; Demchyshyn L; Glennon RA
Bioorg Med Chem; 2001 Mar; 9(3):613-9. PubMed ID: 11310595
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors.
Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C
J Med Chem; 1998 Dec; 41(25):5070-83. PubMed ID: 9836623
[TBL] [Abstract][Full Text] [Related]
14. 3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
Castro JL; Street LJ; Guiblin AR; Jelley RA; Russell MG; Sternfeld F; Beer MS; Stanton JA; Matassa VG
J Med Chem; 1997 Oct; 40(22):3497-500. PubMed ID: 9357514
[No Abstract] [Full Text] [Related]
15. SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity.
Selkirk JV; Scott C; Ho M; Burton MJ; Watson J; Gaster LM; Collin L; Jones BJ; Middlemiss DN; Price GW
Br J Pharmacol; 1998 Sep; 125(1):202-8. PubMed ID: 9776361
[TBL] [Abstract][Full Text] [Related]
16. SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors.
Price GW; Burton MJ; Collin LJ; Duckworth M; Gaster L; Göthert M; Jones BJ; Roberts C; Watson JM; Middlemiss DN
Naunyn Schmiedebergs Arch Pharmacol; 1997 Sep; 356(3):312-20. PubMed ID: 9303567
[TBL] [Abstract][Full Text] [Related]
17. 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
Heightman TD; Gaster LM; Pardoe SL; Pilleux JP; Hadley MS; Middlemiss DN; Price GW; Roberts C; Scott CM; Watson JM; Gordon LJ; Holland VA; Powles J; Riley GJ; Stean TO; Trail BK; Upton N; Austin NE; Ayrton AD; Coleman T; Cutler L
Bioorg Med Chem Lett; 2005 Oct; 15(19):4370-4. PubMed ID: 16039851
[TBL] [Abstract][Full Text] [Related]
18. 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine.
Jorand-Lebrun C; Pauwels PJ; Palmier C; Moret C; Chopin P; Perez M; Marien M; Halazy S
J Med Chem; 1997 Nov; 40(24):3974-8. PubMed ID: 9397179
[TBL] [Abstract][Full Text] [Related]
19. Differentiation between partial agonists and neutral 5-HT1B antagonists by chemical modulation of 3-[3-(N,N-dimethylamino)propyl]-4-hydroxy- N-[4-(pyridin-4-yl)phenyl]benzamide (GR-55562).
Lamothe M; Pauwels PJ; Belliard K; Schambel P; Halazy S
J Med Chem; 1997 Oct; 40(22):3542-50. PubMed ID: 9357521
[TBL] [Abstract][Full Text] [Related]
20. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein.
Cohen ML; Schenck K
J Pharmacol Exp Ther; 1999 Sep; 290(3):935-9. PubMed ID: 10454462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
